Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of High-Dose Rifampicin and Pyrazinamide in a Shorter Tuberculosis Treatment
NCT04694586Phase 2Suspended
- Start
- Nov 2022
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin and pyrazinamide in pulmonary tuberculosis (TB) (2 arms). Primary endpoint: Area under the plasma concentration-time curve of pyrazinamide at 14 days. Started Nov 2022; status: suspended.
02
Drugs
rifampicinpyrazinamide
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT04694586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04694586.